AS170014-A4-Yammine

The below study is currently at the planning grant stage. These details are pulled from draft protocol being prepared for funding consideration.

Protocol Title: An Aldehyde Dehydrogenase 2 Inhibitor, ANS-6637, for Reducing Symptoms of Post-Traumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) in Veterans

Objective:

The objective of this study is to determine if, compared to placebo, ANS-6637, an ALDH2 inhibitor is a safe and potentially efficacious treatment for PTSD and AUD in Veterans with comorbid PTSD and AUD


Hypothesis:

Treatment with ANS-6637 will decrease both PTSD symptoms and the proportion of heavy drinking days, compared to treatment with placebo.

 

Primary Inclusion Criteria: Veterans with both PTSD and AUD. 


Subject Completion Target: n = 80


Study Synopsis: 

This is a randomized, double-blind, placebo-controlled study to examine the ability of the 8-week treatment with ANS-6637 to reduce symptoms of both PTSD and AUD

 

This study will be conducted at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC). The MEDVAMC is part of the BCM and the Texas Medical Center (TMC).